FDA Analysis: Metastatic NSCLC Treated With Anti–PD-1 Therapy Past RECIST Progression

June 3-7, 2016; Chicago, Illinois
Evaluation of patients with metastatic NSCLC treated past first RECIST defined progression with anti–PD-1 therapy in clinical trials finds that a small proportion (8%) attained a subsequent response to treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 548 KB
Released: June 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

Downloadable slideset on the use of neoadjuvant immunotherapy in resectable early-stage lung cancer, from Clinical Care Options (CCO)

Released: December 1, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on EGFR Exon 20–Altered NSCLC.

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Released: December 1, 2021

PDF transcript of a podcast where lung cancer experts answer clinical questions on evolving immunotherapy strategies for NSCLC, from Clinical Care Options (CCO)

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: December 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue